Search AI Products and News

Today, on the second anniversary of Baichuan Intelligent's founding, the company's founder and CEO Wang Xiaochuan released an all-staff letter, reviewing the past two years' achievements and shortcomings, and clarifying the company's current and future development direction. Wang Xiaochuan emphasized that Baichuan Intelligent will firmly pursue its technological vision and business direction in the medical field, promoting the deep application of AI technology in the medical industry through the path of "creating doctors - changing paths - promoting medicine".

A medical team at Ningbo University Affiliated People's Hospital recently used artificial intelligence to successfully detect early-stage pancreatic cancer in a seemingly routine case. 65-year-old Mr. Qiu visited the hospital due to dizziness for three consecutive days. While routine examinations revealed no abnormalities, the AI system, through in-depth analysis of his imaging data, issued a timely alert indicating a potential risk of pancreatic cancer. This case utilized a "Plain CT Scan + AI" approach, a cutting-edge technology that...

Insilico Medicine, a biopharmaceutical company focused on generative artificial intelligence, today announced the successful completion of a $110 million Series E financing round. The round was led by a private equity fund under Value Partners Group (HKG:0806), Pudong New Area Investment, Shanghai Pudong Development Bank Group, Xicheng Capital, and Yixing Guokong. Several new investors focused on the industry and technology sectors also participated, alongside continued support from existing investors.

Insilico Medicine recently announced the closing of a $110 million Series E financing round, led by Value Partners, a Hong Kong-based firm, with participation from existing and new investors. The funds will be used to refine the company's AI models and support pivotal clinical trials for its lead candidate drug in idiopathic pulmonary fibrosis. The company's small molecule inhibitor, ISM001-055, was recently officially named rentosertib by the U.S. Adopted Names Council, marking a significant milestone for this AI-generated drug candidate.

A German research team has developed and released FIORA, an open-source graph neural network (GNN) model designed to improve the accuracy of mass spectrometry analysis. This advancement is expected to significantly contribute to the progress of precision medicine.

Hunan's medical security bureau recently issued a notice prohibiting the use of artificial intelligence to automatically generate prescriptions in online hospitals. This regulation has drawn significant attention, particularly given the increasing prevalence of internet-based healthcare services. The notice mandates that prescriptions must be issued by licensed physicians who have personally interacted with the patient or their family, ensuring compliance with existing regulations.

A significant advancement in Chinese medicine has been achieved with the recent clinical deployment of "Xiehe-Taichu," a rare disease AI model jointly developed by Peking Union Medical College Hospital and the Institute of Automation, Chinese Academy of Sciences. This marks a breakthrough in China's rare disease diagnostic technology and provides a new tool for improving clinical efficiency. The development of this AI model benefits from years of accumulated knowledge on rare diseases in China and the support of genetic testing data from the Chinese population. As the world's first rare disease model tailored to the characteristics of the Chinese population, it...

The Qichacha APP shows that on February 10, Shandong University of Traditional Chinese Medicine released a correction announcement for the smart course construction project (3008), stating that for packages 1, 2, and 3, the project requirements and technical specifications have added "Integration Requirement Importance: General; Technical Specifications: Ability to integrate with DeepSeek model." The budget for package 1 is 2 million yuan, for package 2 is 800,000 yuan, and for package 3 is 1.4 million yuan.

At the recent World Economic Forum in Davos, Google DeepMind's CEO Demis Hassabis stated that the first drugs designed with the help of artificial intelligence could begin clinical trials by 2025. Hassabis also heads Isomorphic Labs, a drug research company under DeepMind. He stated, "Our plan is to have some AI-designed drugs enter clinical trials by the end of this year."

In the healthcare sector, the combination of artificial intelligence (AI) and genomics has reached an exciting new milestone. Recently, Cerebras Corporation partnered with Mayo Clinic to unveil a revolutionary genomic foundation model at the JP Morgan Healthcare Conference in San Francisco. This model aims to leverage advanced AI technology and high-performance computing (HPC) to drive advancements in genomics, particularly in personalized medicine. The new genomic model focuses on improving diagnostic accuracy and personalized treatment options, with preliminary applications in

With the continuous advancement of technology, artificial intelligence (AI) has become a key factor in improving the quality of life for the elderly. Surveys show that 92% of seniors prefer to spend their later years in their own homes. The involvement of AI not only ensures their safety but also maintains their independence. In the face of potential emergencies that elderly individuals may experience while home alone, such as falls, strokes, or heart attacks, AI offers effective solutions. In fall detection, AI algorithms have been trained on large datasets to enhance the accuracy in distinguishing between daily activities and actual falls, reducing...

Google's HeAR bioacoustic model detects various diseases such as tuberculosis, COVID-19, and chronic obstructive pulmonary disease by analyzing sounds, trained on 313 million audio clips, demonstrating exceptional diagnostic capabilities. HeAR outperforms existing models in multiple health acoustic events, cough, and lung function inference tasks, particularly excelling in detecting COVID-19 and tuberculosis. Salcit Technologies has applied HeAR in its product Swaasa® for lung assessment.

SoftBank Group has partnered with Tempus AI to create a new joint venture aimed at utilizing artificial intelligence (AI) to analyze personal medical data and provide treatment recommendations. SoftBank Group CEO Masayoshi Son announced the news at a press conference in Tokyo.